TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE: BVF)(TSX: BVF) today announced that the Company has received the 2009 Corporate Award from the National Organization for Rare Disorders (NORD) for the development of Xenazine® for the treatment of chorea in association with Huntington’s disease. The Award was presented last night at NORD’s Partners in Progress Gala in Washington D.C.
